Evidence map›Paper›PMID 40178277›Full record

ArticleEuropean journal of neurology2025

Fatigue in the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 3.

Zhi-Li Chen, Li-Mei Xiao, Chun Li, Liang-Liang Qiu, Wei Lin, Zhi-Xian Ye, Yuan-Yuan Zhang, Zhi-Bao Zhu, Meng-Cheng Li, Min-Ting Lin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhi-Li ChenDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Li-Mei XiaoDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Chun LiDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Liang-Liang QiuDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Wei LinDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Zhi-Xian YeDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Yuan-Yuan ZhangDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Zhi-Bao ZhuDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Meng-Cheng LiDepartment of Radiology of First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
Min-Ting LinDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Wan-Jin ChenDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Ning WangDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
Ying FuDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.ORCID https://orcid.org/0000-0002-1590-3945
Shi-Rui GanDepartment of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, China.
OSCCAR Investigators

Funding

Joint Funds for the Innovation of Science and Technology of Fujian Province 2021Y9128Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province 2022ZQNZD005National Natural Science Foundation of China U21A20360
6 · The paper itself

Abstract

objectiveFatigue is a significant symptom in patients with spinocerebellar ataxia type 3 (SCA3). This study explores the role of fatigue in SCA3, examining its impact on quality of life and its potential as an indicator of disease progression.

methodsWe prospectively recruited 128 molecularly confirmed SCA3 patients and 125 sex-, age-, and education-matched healthy controls (HCs). Age at onset, disease duration, length of normal and expanded CAG repeats, and 14-item Fatigue Scale score were compared. MRIs evaluated the cerebellum and brain lesions.

resultsOur study found that the preataxic SCA3 group exhibited lower fatigue incidence and score than HCs (Incidence: 13% vs. 36%, p = 0.031; FS-14 score: 3.0 ± 2.7 vs. 5.6 ± 2.8, p < 0.001). Ataxic SCA3 patients experienced significantly higher fatigue incidence and score compared to both the preataxic SCA3 group (Incidence: 63.8% vs. 13%, p < 0.001; FS-14 score: 8.1 ± 3.9 vs. 3.0 ± 2.7, p < 0.001) and HCs (Incidence: 63.8% vs. 36%, p < 0.001; FS-14 score: 8.1 ± 3.9 vs. 5.6 ± 2.8, p < 0.001). Moreover, fatigue severity in SCA3 correlated with disease duration and expanded CAG repeat length. Neuroanatomical correlations revealed volume reductions in cortical and cerebellar regions linked to higher physical and mental fatigue scores in SCA3 patients.

conclusionsMonitoring fatigue effectively evaluates a patient's overall quality of life and disease progression, making it a key indicator. Future treatments can target specific brain regions, with their effectiveness being evaluated through FS-14 assessments of fatigue changes.

Indexed as

FatigueMachado-Joseph DiseaseAdultAgedBrainDisease ProgressionFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedProspective StudiesQuality of Lifecerebellar volumecortical volumefatiguemagnetic resonance imagingspinocerebellar ataxia type 3 (Machado‐Joseph disease)

Identifiers

PMID40178277
PMCPMC11966824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.